Compare ON Holding AG (ONON) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Vertex Pharmaceuticals Incorporated — how do they compare? ON Holding AG trades at $33.94 (market cap $11.10B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.5× ON Holding AG's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ONON | VRTX | |
|---|---|---|
Market Cap | $11.10B | $128.16B |
Volume | 8,202,649 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $557.96 |
52-Week Low | $26.76 | $407.37 |
Typical Hold Time | 22 Days | 120 Days |
Enterprise Value | $10.26B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $33.22, up 0.27% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $0.44 vs. $0.42, maintaining a three-quarter beat streak. Recent investor day announcements include a $1 billion buyback program and ambitious 2029 targets of CHF 5.6B in sales with 22% EBITDA margins, driving positive sentiment.
The stock offers growth potential with 74% analyst buy ratings and a $42.26 consensus target, representing 27% upside. Key risks include elevated valuation multiples (P/E 23.41, P/S 5.52) and competitive pressure in footwear. Strong cash flow generation ($359.5M operating cash flow in 2025) supports the buyback and expansion plans.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
